A $25 billion biotech"s stock is popping on its promising cancer data (INCY)

Incyte, a $25 billion biotech company, debuted some new data about its cancer drugs on Wednesday, and the stock popped.  The drugmaker, which has one app.....»»

Category: topSource: businessinsiderMay 18th, 2017

The Wall Street Journal: Celgene might buy CAR-T biotech Juno Therapeutics

Juno is one of several companies pioneering a cancer treatment called CAR-T, which is new and very promising......»»

Category: topSource: marketwatchJan 17th, 2018

AstraZeneca"s Lung Cancer Study Data Promising, Shares Spike

AstraZeneca, (AZN) releases data from a late-stage study on Imfinzi which showed that the new cancer drug led to superior progression-free survival to standard of care in lung cancer patients. AstraZeneca, plc A.....»»

Category: worldSource: nytSep 11th, 2017

Why Cancer Biotech Clovis Oncology’s Stock Is Soaring

Impressive ovarian cancer drug data could make life hard for its rivals. Cancer-focused biotech Clovis Oncology’s stock spiked nearly 50% in early Monday trading after the company announced impressive clinical t.....»»

Category: europeSource: fortuneJun 19th, 2017

Biotech Stock Roundup: Biogen Gains on Strong Q1, NASH Data on Gilead Drug

Focus this week remained on Biogen's (BIIB) first quarter results which surpassed expectations. Earnings season for the biotech sector is off to a promising start with Biogen BIIB report.....»»

Category: topSource: zacksApr 26th, 2017

Biotech Stock Roundup: Alexion Reports 4Q Results, Celgene MS Drug Looks Promising

While Alexion (ALXN) reported a mixed quarter, Celgene provided promising data on a pipeline candidate. Key updates in the biotech sector include a mixed quarter from Alexion ALXN and promising data on Celgene&r.....»»

Category: topSource: zacksFeb 22nd, 2017

Biotech Stock Roundup: Regeneron"s Praluent to Remain on Market for Now, GILD Presents HIV Data

Gilead (GILD) presented promising HIV data while Regeneron's PCSK9 inhibitor will remain on the market during the appeals process. Regeneron REGN got a bit of a boost w.....»»

Category: topSource: zacksFeb 15th, 2017

Bluebird Bio Flies; Blood Cancer Drug Impresses In Small Trial

Two biotech stocks are climbing today thanks to the results of one small drug trial testing a new type of treatment for multiple myeloma Bluebird bio (BLUE) surged more than 18% today after data from a Phase 1 study released late Wednesday showed that .....»»

Category: blogSource: barronsDec 1st, 2016

Tesaro: Priced for a Takeover?

Shares of Tesaro (TSRO) are soaring today after the biotech company reported positive data for its treatment of ovarian cancer over the weekend. Credit Suisse analyst Alethia Young and team contend that "M&A remains in focus" for Tesaro following the data.....»»

Category: blogSource: barronsOct 10th, 2016

Biotech M&A takes off as Sanofi and Celgene spend $20 billion

LONDON (Reuters) - Biotech deal activity exploded on Monday with French drugmaker Sanofi and U.S.-based Celgene spending a combined total of more than $20 billion to add new products for hemophilia and cancer to their medicine cabinets......»»

Category: topSource: reuters20 min. ago

Biotech M&A takes off as Sanofi and Celgene spend $20 billion

LONDON, Jan 22 (Reuters) - Biotech deal activity exploded on Monday with French drugmaker Sanofi and U.S.-based Celgene spending a combined total of more than $20 billion to add new products for hemophilia and cancer to their medicine cabinets......»»

Category: topSource: foxnews33 min. ago

Celgene to acquire Juno Therapeutics for $9 billion, or $87 a share

Celgene Corp. on Monday said it's reached a deal to buy Juno Therapeutics Inc., a biotech company developing cancer treatments, for $9 billion, or $87 a share in cas.....»»

Category: topSource: marketwatch4 hr. 5 min. ago

Fledgling Biotech Company"s Stock Surges

Iovance Biotherapeutics develops cancer immunotherapy treatmentsRelated Stocks: IOVA, JUNO, CELG,.....»»

Category: smallbizSource: nytJan 19th, 2018

Cancer Space Update: Label Expansions, Data Readouts in Focus

This week the cancer space was abuzz with news of label expansion of Kyprolis, Lynparza and Kymriah and positive data readouts for Cabometyx an.....»»

Category: dealsSource: nytJan 19th, 2018

Blood test to detect 8 cancers early gives promising results

Scientists are reporting progress on a blood test to detect many types of cancer at an early stage, including some of the most deadly ones that lack screening tools now......»»

Category: topSource: foxnewsJan 18th, 2018

Juno and Boeing climb while Goldman Sachs and GE drop

Stocks that moved substantially or traded heavily Wednesday: Juno Therapeutics Inc., up $23.65 to $69.25 The Wall Street Journal reported that biotech drugmaker Celgene may buy the cancer therapy company......»»

Category: topSource: foxnewsJan 17th, 2018

Juno Therapeutics jumps 53% after report Celgene is interested in buying the cancer drugmaker

Markets Insider Shares of Juno Therapeutics are up more than 50% in early trading on Wednesday following a Wall Street Journal report Tuesday evening that biotech giant Celgene is in talks to buy the cancer dr.....»»

Category: topSource: businessinsiderJan 17th, 2018

The hottest thing in cancer drug development is a takeover target again — here"s what you need to know about it (JUNO, CELG)

AP Biotech giant Celgene is in talks to acquire Juno Therapeutics, The Wall Street Journal reported on Tuesday. If the deal goes through, it'd be the second deal in the past few months for companies working on treatments that.....»»

Category: topSource: businessinsiderJan 17th, 2018

The Hot Stock: Merck Gains 5.8%

Data from the latest trial of Merck's blockbuster cancer treatment helped propel the stock to the top of the S&P 500 Tuesday......»»

Category: blogSource: barronsJan 16th, 2018

Brainstorm Health: Universal Flu Vaccine, Merck Lung Cancer Drug, UnitedHealth Earnings

Brainstorm Health Daily: January 16, 2018 Hello, readers! This is Sy. Google parent Alphabet’s venture arm GV (formerly Google Ventures) is among the companies backing U.K. biotech Vaccitech, which has set out to achieve one.....»»

Category: europeSource: fortuneJan 16th, 2018